1. Home /
    2. Altai Protocol Library /
  2. New Drug: Margetuximab for her2-positive metastatic breast cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Drug: Margetuximab for her2-positive metastatic breast cancer

New Drug: Margetuximab for her2-positive metastatic breast cancer
Study:
  • Phase 3 trial (SOPHIA) in pts with disease progression after >=2 lines of anti-her2 therapy
  • Chemotherapy with margetuximab (n=266) vs. trastuzumab (n=270)
Efficacy:
  • ORR: 22% vs. 16%
  • Median PFS: 5.8 vs. 4.9 mos (HR: 0.76 [0.59-0.98])
  • Median OS: 21.6 vs. 19.8 mos (HR: 0.89 [0.69-1.13])
Safety:
  • Grade 3-4 AEs: 52% vs. 48%

Presented at 2019 SABCS

Rugo HS, et al. Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis

https://www.abstractsonline.com/pp8/#!/7946/presentation/2038

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More